Analysts are intrested in these 5 stocks: ( (CVNA) ), ( (ZS) ), ( (MPLX) ), ( (EPD) ) and ( (TMO) ). Here is a breakdown of their recent ratings and the rationale behind them.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Carvana Co. is making waves in the used vehicle market, with analyst Joseph Spak initiating coverage with a Buy rating and a $450 price target. Spak highlights Carvana’s innovative online platform and exceptional customer experience as key differentiators in a fragmented market. With a forecasted EBITDA growth of 25% CAGR through the decade, Carvana is poised for significant market share expansion. The company’s focus on consumer experience and efficient vehicle acquisition strategy are expected to drive growth, making it a compelling investment opportunity.
Zscaler, a player in the cybersecurity sector, has been downgraded to Hold by analyst Peter Weed, with a price target of $264. Despite Zscaler’s strong performance, concerns about increased competition and narrative issues around growth have led to a more cautious outlook. While the company remains well-positioned, its premium valuation is challenged by uncertainties in growth persistence. Investors are advised to consider alternatives like Palo Alto for potential upside in the cybersecurity space.
MPLX has been downgraded to Hold by analyst Jeremy Tonet, with a price target of $57. The company’s year-to-date outperformance has reduced its relative attractiveness compared to peers. Despite its strong operational performance and integrated NGL strategy, MPLX faces limited near-term catalysts. However, its defensive positioning and healthy dividend yield provide some downside protection, making it a stable, if not high-growth, investment.
Enterprise Products Partners has also been downgraded to Hold by Jeremy Tonet, with a $35 price target. While EPD boasts a strong track record and financial flexibility, its growth prospects are overshadowed by peers offering higher returns. The company’s recent joint venture with ExxonMobil and increased buyback authorization are positive developments, but operational challenges and lower institutional interest in MLPs present headwinds.
Thermo Fisher Scientific has received a Buy rating from analyst Kallum Titchmarsh, with a $670 price target. The company is expected to benefit from accelerated share gains in its Analytical Instruments segment, particularly in mass spectrometry and electron microscopy. With a diversified revenue base and recovering end markets, Thermo Fisher is well-positioned for growth in 2026. The company’s strategic initiatives and strong market presence make it an attractive investment in the life sciences sector.